# A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct03018938` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03018938](<https://clinicaltrials.gov/study/NCT03018938>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03018938

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 814 participants.

## Technical summary

Registry record NCT03018938. Randomized; no masking; primary purpose treatment. Start 2017-02-06 (actual); primary completion 2019-02-19 (actual). Results posted on 2020-03-18.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 814 participants (enrolled count; ClinicalTrials.gov record NCT03018938, source copy `cardio:ctgov-nct03018938-2020-03-18`, retrieved 2026-10-26)
- Started: 2017-02-06 (actual) (ClinicalTrials.gov record NCT03018938, source copy `cardio:ctgov-nct03018938-2020-03-18`, retrieved 2026-10-26)
- Primary completion: 2019-02-19 (actual) (ClinicalTrials.gov record NCT03018938, source copy `cardio:ctgov-nct03018938-2020-03-18`, retrieved 2026-10-26)
- Completion: 2019-07-12 (actual) (ClinicalTrials.gov record NCT03018938, source copy `cardio:ctgov-nct03018938-2020-03-18`, retrieved 2026-10-26)
- Results first posted: 2020-03-18 (ClinicalTrials.gov record NCT03018938, source copy `cardio:ctgov-nct03018938-2020-03-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03018938, source copy `cardio:ctgov-nct03018938-2020-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03018938-2020-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus
- Acronym: CLASSIC
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin Analog Mid Mixture
- Intervention (Drug): Basal Insulin Analog
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 35e7b560963296317958636c0ff5a6a3b59ed488c18cd1d0b758f34f2311fac2
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
